<DOC>
	<DOCNO>NCT01401322</DOCNO>
	<brief_summary>Time-to-Progression ( TTP )</brief_summary>
	<brief_title>Single Agent Lenalidomide Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>Determine time-to-progression ( TTP ) subject relapsed/refractory acute lymphoblastic leukemia ( ALL ) receive single agent lenalidomide 50 mg/day 28 days/cycle .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Relapsed refractory acute lymphoblastic leukemia ( ALL ) &gt; 10 % bone marrow peripheral blood blast per WHOcriteria . Refractory define failure achieve CR prior therapy . Previously untreated patient &gt; 60 , candidate standard induction Age ≥ 18 Not candidate curative treatment regimen Unwilling unable receive conventional chemotherapy ECOG performance status ≤ 2 Life expectancy &gt; 2 month Registered RevAssist restricted distribution program , willing able comply program requirement Females childbearing potential ( FCBP ) : Must negative serum urine pregnancy test ( sensitivity least 50 mIU/mL ) 10 14 day prior study enrollment within 24 hour prior prescribe lenalidomide Must either commit continue abstinence heterosexual intercourse begin two acceptable method birth control Agree ongoing pregnancy test Men must agree use latex condom sexual contact FCBP Able adhere study visit schedule protocol requirement Willing able understand voluntarily sign write informed consent Prior therapy lenalidomide History intolerance thalidomide include development erythema nodosum take thalidomide similar drug Advanced malignant hepatic tumor . Concomitant treatment antineoplastic agent ( exception hydroxyurea ) Antineoplastic treatment le 4 week prior enrollment ( exception hydroxyurea ) Use experimental drug therapy within 14 day baseline Inability swallow absorb drug Active opportunistic infection treatment opportunistic infection within 4 week first dose study drug New York Heart Association Class III IV heart failure Unstable angina pectoris Cardiac arrhythmia rapid ventricular response ( heart rate &gt; 100 beats/minute ) Uncontrolled psychiatric illness would limit compliance requirement Known HIV infection Known active hepatitis B virus ( HBV ) ( exception seropositivity due HBV vaccine consider active HBV ) Known hepatitis C virus ( HCV ) infection Pregnant Lactating female must agree breastfeed take lenalidomide Other medical psychiatric illness organ dysfunction laboratory abnormality opinion investigator would compromise patient 's safety interfere data interpretation Creatinine ≥ 1.5 mg/dL Creatinine clearance ≤ 60 mL/min . Total bilirubin &gt; 1.5 x institutional upper limit normal ( ULN ) ( exception document Gilbert 's syndrome ) AST ALT &gt; 3 x institutional ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>